Filgrastim biosimilar - Merck & Co.
Alternative Names: INS-19; MK-4214Latest Information Update: 05 Nov 2023
At a glance
- Originator Insmed
- Developer Insmed; Merck & Co
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor replacements; Granulocyte colony-stimulating factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neutropenia
Most Recent Events
- 29 Aug 2013 No development reported - Phase-I for Neutropenia in USA (SC)
- 29 Aug 2013 No development reported - Phase-III for Neutropenia in Latvia (SC)
- 28 Oct 2011 Phase-III clinical trials in Neutropenia in Latvia (SC)